Altered hemostasis in pulmonary hypertension

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 2, 1998, Pages 107-117

  Hassell, K L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Animal studies; Coagulation; Human studies; Pulmonary hypertension; Review

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; THROMBOMODULIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; FIBRINOLYSIS; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

EID: 0031978680     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199803000-00001     Document Type: Review

References (64)

1. Hughes JD, Rubin LJ. Primary pulmonary hypertension: an analysis of 28 cases and a review of the literature. Medicine 1986; 65: 56-72.
2. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGood MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
3. Wagenvoort ÇA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42: 1163-1184.
4. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart Lung and Blood Institute PPH Registry. Circulation 1989; 80: 1198-1206.
5. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clinic Proc 1985; 60: 16-25.
6. Hitano S, Strasser T, eds. Primary pulmonary hypertension: report on a WHO meeting. Geneva: WHO; 1975. p. 9.
7. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and element of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275285.
8. Weiss HJ, Turitto VT, Baumgartner HR. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. / Clin Invest 1986; 78: 10721082.
9. Plow EF, Ginsberg MH. Molecular basis of platelet function. In: Huffman R, Benz EJ Jr, Shattil SJ, Cohen HJ, Silberstein LE (editors). Hematology: basic principles and practice. Edinburgh: Churchill Livingstone; 1995. pp. 1524-1535.
10. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986; 46: 185.
11. Archipoff G, Beretz A, Freyssinet J, Klein-Soyer C, Brisson C, Cazenave J. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue factor activities on the surface of human saphenous vein endothelial cells in culture following stimulation by interleukin 1, tumor necrosis factor, thrombin, or phorbol ester. BiochemJ 1991; 273: 679-684.
12. Grabowski EF, Zukerman DB, Nemerson Y. The functional expression of tissue factor by fibroblasts and endothelial cells under flow conditions. Blood 1993; 81: 3265-3270.
13. 13: Takano S, Kimura A, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-2029.
14. Brody JI, Pickerin NG, Fink GB. Abnormalities of thrombomodulin and tissue plasminogen activator in occluded aortocoronary grafts detected by immunohistochemistry. Trans Assoc Am Phys 1988; 101: 79-87.
15. Kawai Y, Watanabe K, Yamamoto H, Satoh K Murata M, Harda M, Illeda Y. Effects of shear stress on fibrinolytic activity of cytokine treated endothelial cells [abstract]. Thromb Haemost 1993; 69: 581.
16. Ryan ÜB. The endothelial surface and response to injury. Fed Proc 1986; 45: 101-108.
17. Hassoun PM, Thompson TB, Steigman D, Hales CA. Effect of heparin and warfarin on chronic hypoxic pulmonary hypertension and vascular remodeling in the guinea pig. Am Rev Respir 1989; 139: 763-768.
18. Meyrick B, Gamble \V, Reid L. Development of Crotolaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol 1980; 239 (Heart Circ Phys 8): H692-H702.
19. Merkow L, Kleinerman J. An electron microscopic study of pulmonary vasculitis induced by monocrotaline. Lab Invest 1966; 15: 547-564.
20. Gillespie MN, Goldbulm SE, Cohen DA, Mclain CJ. Interleukin 1 bioactivity in the lungs of rats with monocrotaline-induced pulmonary hypertension. Proc Soc Exp Biol Med 1988; 187: 26-32.
21. Voelkel NF, Tuder RM, Bridges J, Arend WP. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 1994; 11: 664-675.
22. Steele P, Ellis JH, Weily HS, Genton E. Platelet survival time in patients with hypoxemia and pulmonary hypertension. Circulation 1977; 55: 660-662.
23. Lopes AAB, Maeda NY, Ebaid M, Chamone DF, Pileggi F. Effect of intentional hemodilution on platelet survival in secondary pulmonary hypertension. Chest 1989; 95: 1207-1210.
24. Hervé P, Drouet L, Dosquet C, Launay JM, Rain B, Simonneau G, et al. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med 1990; 89: 117120.
25. Hervé P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
26. Rostagno C, Frisco D, Boddi M, Poggesi L. Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Eiir Respir J 1991; 4: 147-151.
27. Gensini GF, Rostagno C, Pezza A, Fanara F, Castellani S, Frisco D, et al. Effects of dipyridamole infusion on local platelet aggregation and local formation of thromboxane A2 in patients with pulmonary hypertension. In: Neri Serneri GG (editor). Advances in prostaglandin, thromboxane, and lettkotriene research. New York: Raven Press; 1985. Vol. 13.
28. Nenci GG, Berrettini M, Todisco T, Parise P. Enhanced plasma beta-thromboglobulin in hypoxaemia: effects of dipyridamole [letter]. N Engl J Med 1981; 304: 1044.
29. Sculman LL, Grossman BA, Owen J. Platelet activation and fibrinopeptide formation in pulmonary hypertension. Chest 1993; 104: 1690-1693.
30. White SM, Roth RA. Pulmonary platelet sequestration is increased following monocrotaline pyrrole treatment of rats. ToxicolAppl Pharmacol 1988; 96: 465-475.
31. Kentera D, Zdravkovic M, Rolovic Z, Susie D. Platelets in rats with chronic normobaric hypoxic pulmonary hypertension. Respiration 1985; 48: 159163.
32. Hilliker KS, Bell TG, Lorimer D, Roth RA. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension. Am J Physiol 1984; 246: H747-H753.
33. Ganey PE, Sprugel KH, White SM, Wagner JG, Roth RA. Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia. Am J Physiol 1988; 24: H1165-H1172.
34. Ganey PE, Roth RA. 5-Hydroxytryptamine and thromboxane in platelets from rats treated with monocrotaline pyrrole. Toxicol Appl Pharmacol 1987; 88: 157-164.
35. Hilliker KS, Bell TG, Roth RA. Monocrotaline pyrrole-induced pulmonary hypertension in fawn-hooded rats with platelet storage pool deficiency: 5-hydroxytryptamine uptake by isolated, perfused lungs. Thromb Haemost 1983; 50: 844-847.
36. Kentera D, Susie D, Velijkovic V, Tucakovic G, Koko V. Pulmonary artery pressure in rats with hereditary platelet function defect. Respiration 1988; 54: 110-114.
37. Ashmore RC, Rodman DM, Sato K, Webb SA, O'Brien RF, McMurtry IF, et al. Paradoxical constriction to platelets by arteries from rats with pulmonary hypertension. Am J Physiol 1991; 260: H1929-H1934.
38. Ohar JA, Waller KS, deMello D, Lagunoff D. Administration of chronic intravenous platelet-activating factor induces pulmonary arterial atrophy and hypertension in rabbits. Lab Invest 1991; 65: 451-458.
39. McCormack DG, Barnes PJ, Evans TW. Plateletactivating factor: evidence against a role in hypoxic pulmonary vasoconstriction. Crit Care Med 1990; 18: 1398-1402.
40. Ross R. Platelet-derived growth factor. Lancet 1989; i: 1179-1182.
41. Czer GT, Marsh J, Konopka R, Moser KM. Lowdose PGI2 prevents monocrotaline-induced thromboxane production and lung injury. / Appl Physiol 1986; 60: 464-471.
42. Schultze AE, Emeis JJ, Roth RA. Cellular fibronectin and von Willebrand factor concentrations in plasma of rats treated with monocrotaline pyrrole. Biochem Pharmacol 1996; 51: 187-191.
43. Rabinovitch M, Andrew M, Thorn H, Trusler GA, Williams WG, Rowe RD, et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987; 76: 1043-1052.
44. Lopes AAB, Maeda NY, Aiello VD, Ebaid M, Bydlowski SP. Abnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension. Chest 1993; 104: 1455-1460.
45. Lopes AAB, Maeda NY. Abnormal degradation of von Willebrand factor main subunit in pulmonary hypertension. EnrRespir] 1995; 8: 530-536.
46. Geggel RL, Carvalho CA, Hoyer LW, Reid LM. von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis 1987; 135: 294-299.
47. Welsh CH, Hassell KH, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110: 710-717.
48. Inglesby TV, Singer JW, Gordon DS. Abnormal fibrinolysis in familial pulmonary hypertension. Am J Med 1973; 55: 5-14.
49. Cacoub P, Karmochkine M, Dorent R, Nataf P, Piette JC, Godeau P, et al. Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med 1996; 101: 160-164.
50. Ellison RC, Brown J. Fibrinolysis in pulmonary vascular disease. Lancet 1965; i: 786-788.
51. Tubbs RR, Levin RD, Shirey EK, Hoffman G. Fibrinolysis in familial pulmonary hypertension. Am J Clin Pathol 1977; 71: 384-387.
52. Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder B. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994; 150: 929-933.
53. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990; 82: 841-847.
54. Wojta J, Jones RL, Binder BR, Hoover RL. Reduction in PU2 decreases the fibrinolytic potential of cultured bovine endothelial cells derived from pulmonary arteries and lung microvasculature. Blood 1988; 71: 1703-1706.
55. Schultze AE, Roth RA. Procoagulant and fibrinolytic properties of bovine endothelial cells treated with monocrotaline pyrrole. Toxicol Appl Pharmacol 1993; 122: 7-15.
56. Schultze AE, Roth RA. Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole. Toxicol Appl Pharmacol 1993; 121: 129-137.
57. Rich S, Hart K. Familial pulmonary hypertension in association with an abnormal hemoglobin: insights into the pathogenesis of pulmonary hypertension. Chest 1991; 99: 1208-1210.
58. Rostagno C, Prisco D, Abate R, Poggesi L. Pulmonary hypertension associated with longstanding thrombocytosis. Chest 1991; 99: 1303-1305.
59. Hultin MD, Hoffman CF, Groth ML. The prothrombin fragment F1.2 assay: comparison of anticoagulants for diagnosis of hypercoagulability in primary pulmonary hypertension and other disorders [abstract]. Thromb Haemost 1993; 96: 675.
60. Rich S, Kaufmann E, Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
61. Frank H, Gurtner HP, Kneussl M, Levy I, Mlezoch J. Aminorex-induzietre, plexogene pulmonale Arteriopathie: 25 Jahre danach. Z Kardiol 1993; 82: 568-572.
62. Hassoun PM, Thompson TB, Hales CA. Partial reversal of hypoxic pulmonary hypertension by hepar- in. Am Rev Respir Dis 1992; 145: 193-196.
63. McLeod AA, Jewitt DE. Drug treatment of primary pulmonary hypertension. Drugs 1986; 31: 177-184.
64. Moncada S, Vane JR. Arachadonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl] Med 1979; 300: 1142-1147.